[go: up one dir, main page]

ES8603879A1 - Procedimiento para preparar (2-oxo-1,2,3,5-tetrahidroimidazo(2,1-b) quinazolinil) oxialquilamidas - Google Patents

Procedimiento para preparar (2-oxo-1,2,3,5-tetrahidroimidazo(2,1-b) quinazolinil) oxialquilamidas

Info

Publication number
ES8603879A1
ES8603879A1 ES544203A ES544203A ES8603879A1 ES 8603879 A1 ES8603879 A1 ES 8603879A1 ES 544203 A ES544203 A ES 544203A ES 544203 A ES544203 A ES 544203A ES 8603879 A1 ES8603879 A1 ES 8603879A1
Authority
ES
Spain
Prior art keywords
formula
oxo
reaction
treatment
tetrahydroimidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES544203A
Other languages
English (en)
Other versions
ES544203A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex USA LLC
Original Assignee
Syntex USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex USA LLC filed Critical Syntex USA LLC
Publication of ES544203A0 publication Critical patent/ES544203A0/es
Publication of ES8603879A1 publication Critical patent/ES8603879A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C07C205/37—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/44—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/56—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups bound to carbon atoms of six-membered aromatic rings and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

PROCEDIMIENTO PARA LA OBTENCION DE 2-OXO-1,2,3,5-TETRAHIDROIMIDAZO2,1-BQUINAZOLINIL)OXIALQUILAMIDAS Y DE SUS SALES DE ADICION DE ACIDO FISIOLOGICAMENTE COMPATIBLES, DE FORMULA (I), EN LA QUE A, Y, R1, R2, R3 Y R4 PUEDEN SER VARIOS TIPOS DE RADICALES Y N VALE 1-6. CONSISTE EN LA REACCION DE UN COMPUESTO DE FORMULA (II), EN LA QUE R6 REPRESENTA HIDROGENO O UN GRUPO ALQUILO, Y LOS DEMAS SIMBOLOS TIENEN EL MISMO SIGNIFICADO QUE EN LA FORMULA (I), CON UN REACTIVO FORMADOR DE AMIDA. LA REACCION SE LLEVA A CABO POR TRATAMIENTO CON AMONIACO O AMINAS PRIMARIAS ADECUADAS, EN UN DISOLVENTE POLAR, A UNA TEMPERATURA COMPRENDIDA ENTRE 100JC Y 200JC. ESTOS COMPUESTOS TIENEN APLICACIONES FARMACOLOGICAS PARA EL TRATAMIENTO DE ESTADOS RELACIONADOS CON LA AGREGACION DE PLAQUETAS Y LA TROMBOSIS.
ES544203A 1983-02-16 1985-06-14 Procedimiento para preparar (2-oxo-1,2,3,5-tetrahidroimidazo(2,1-b) quinazolinil) oxialquilamidas Expired ES8603879A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/467,125 US4490371A (en) 1983-02-16 1983-02-16 N,N-Disubstituted-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-B]quinazolinyl)oxyalkylamides

Publications (2)

Publication Number Publication Date
ES544203A0 ES544203A0 (es) 1986-01-16
ES8603879A1 true ES8603879A1 (es) 1986-01-16

Family

ID=23854465

Family Applications (3)

Application Number Title Priority Date Filing Date
ES529749A Expired ES8604226A1 (es) 1983-02-16 1984-02-15 Procedimiento para preparar (2-oxo-1, 2, 3, 5-tetrahidroimidazo (2, 1-b) quinazolinil) oxialquilamidas
ES544202A Expired ES8603878A1 (es) 1983-02-16 1985-06-14 Procedimiento para preparar (2-oxo-1,2,3,5-tetrahidroimidazo(2,1-b) quinazolinil) oxialquilamidas
ES544203A Expired ES8603879A1 (es) 1983-02-16 1985-06-14 Procedimiento para preparar (2-oxo-1,2,3,5-tetrahidroimidazo(2,1-b) quinazolinil) oxialquilamidas

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES529749A Expired ES8604226A1 (es) 1983-02-16 1984-02-15 Procedimiento para preparar (2-oxo-1, 2, 3, 5-tetrahidroimidazo (2, 1-b) quinazolinil) oxialquilamidas
ES544202A Expired ES8603878A1 (es) 1983-02-16 1985-06-14 Procedimiento para preparar (2-oxo-1,2,3,5-tetrahidroimidazo(2,1-b) quinazolinil) oxialquilamidas

Country Status (20)

Country Link
US (1) US4490371A (es)
EP (1) EP0116948B1 (es)
JP (1) JPS59155383A (es)
KR (1) KR840007727A (es)
AT (1) ATE49210T1 (es)
AU (1) AU572118B2 (es)
CA (1) CA1253862A (es)
DE (1) DE3480925D1 (es)
DK (1) DK70784A (es)
ES (3) ES8604226A1 (es)
FI (1) FI78097C (es)
GR (1) GR79543B (es)
HU (1) HU189886B (es)
IL (1) IL70964A (es)
NO (1) NO164476C (es)
NZ (1) NZ207156A (es)
PL (3) PL143010B1 (es)
PT (1) PT78106B (es)
SU (2) SU1349700A3 (es)
ZA (1) ZA841122B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593029A (en) * 1984-02-15 1986-06-03 Syntex (U.S.A.) Inc. Novel ω-(N-imidazolyl)alkyl ethers of 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones
NZ211117A (en) * 1984-02-15 1987-10-30 Syntex Inc Fused tetrahydroimidazo-(2,1-b)quinazoline derivatives and pharmaceutical compositions
GB8514207D0 (en) * 1985-06-05 1985-07-10 Pfizer Ltd Cardiac stimulants
US4837239A (en) * 1985-08-23 1989-06-06 Syntex (U.S.A.) Inc. Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins
US4670434A (en) * 1985-11-14 1987-06-02 Syntex (U.S.A.) Inc. (2-oxo-3-methylene-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolinyl)oxyalkylamides useful as cyclic AMP phosphodiesterase inhibitors
US4775674A (en) * 1986-05-23 1988-10-04 Bristol-Myers Company Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors
US4701459A (en) * 1986-07-08 1987-10-20 Bristol-Myers Company 7-amino-1,3-dihydro-2H-imidazo[4,5-b]quinolin 2-ones and method for inhibiting phosphodiesterase and blood platelet aggregation
US4761416A (en) * 1986-07-25 1988-08-02 Syntex (U.S.A.) Inc. N-N-disubstituted-ω-[2-amino-3-(carbonylmethyl)-3, 4-dihydroquinazolinyl]oxyalkylamides and related compounds
US4739056A (en) * 1986-11-26 1988-04-19 Syntex (U.S.A.) Inc. N-N-disubstituted-omega-(2-amino-3-(carbonylmethyl)-3,4-dihydroquinazolinyl)oxy-alkylamides and related compounds
NZ234186A (en) * 1989-07-07 1991-10-25 Janssen Pharmaceutica Nv Imidazo quinazolin-one derivatives and pharmaceutical compositions
US4943573A (en) * 1989-11-01 1990-07-24 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility
DE59207016D1 (de) 1991-07-05 1996-10-02 Byk Gulden Lomberg Chem Fab Verwendung substituierter pyridazine gegen dermatosen
US5196428A (en) * 1992-04-03 1993-03-23 Bristol-Myers Squibb Company Imidazo[4,5-b]qinolinyl oxy alkyl ureas
US5348960A (en) * 1992-04-03 1994-09-20 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyl oxy alkyl tetrazolyl piperidine derivatives
US5208237A (en) * 1992-04-03 1993-05-04 Bristol-Meyers Squibb Company 7-oxypropylsulfonamido-imidazo[4,5-b]quinolin-2-ones
US5158958A (en) * 1992-04-03 1992-10-27 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyl oxy alkyl sulfonyl piperidine derivatives
AU3885901A (en) * 1999-09-21 2001-04-24 Emory University Methods and compositions for treating platelet-related disorders
WO2004050657A2 (en) * 2002-11-27 2004-06-17 Artesian Therapeutics, Inc. COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2009002496A (es) * 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
FR2910001B1 (fr) * 2006-12-18 2009-03-20 Sod Conseils Rech Applic Derives d'imidazo, pyrimido et diazepine pyrimidine-dione et leur utilisation comme medicament
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2170930B3 (en) 2007-06-04 2013-10-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
GB0808944D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
GB0808953D0 (en) * 2008-05-16 2008-06-25 Shire Llc substituted quinazolines
GB0808950D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8586587B2 (en) 2009-02-26 2013-11-19 Thar Pharmaceuticals, Inc. Crystalline molecular complex of tadalafil and methylparaben
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN103764672A (zh) 2011-03-01 2014-04-30 辛纳吉制药公司 制备鸟苷酸环化酶c激动剂的方法
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
RS65632B1 (sr) 2013-06-05 2024-07-31 Bausch Health Ireland Ltd Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe
CN114404588A (zh) 2013-08-09 2022-04-29 阿德利克斯公司 用于抑制磷酸盐转运的化合物和方法
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932407A (en) * 1973-11-19 1976-01-13 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
FI59246C (fi) * 1974-06-24 1981-07-10 Otsuka Pharma Co Ltd Foerfarande foer framstaellning av benscykloamidderivat anvaendbara vid trombos- och emboliterapin
US4313947A (en) * 1974-06-24 1982-02-02 Otsuka Pharmaceutical Co., Ltd. Platelet aggregation inhibiting 2-oxyindoles, their compositions and method of use
IE46852B1 (en) * 1977-06-10 1983-10-05 Otsuka Pharma Co Ltd Novel carbostyril derivatives
NL7807507A (nl) * 1977-07-25 1979-01-29 Hoffmann La Roche Tricyclische verbindingen.
FR2512674B1 (fr) * 1981-09-16 1986-01-10 Sandoz Sa Nouveaux derives tricycliques de la quinazolinone, leur preparation et medicaments contenant ces derives
NZ211117A (en) * 1984-02-15 1987-10-30 Syntex Inc Fused tetrahydroimidazo-(2,1-b)quinazoline derivatives and pharmaceutical compositions

Also Published As

Publication number Publication date
SU1493109A3 (ru) 1989-07-07
EP0116948B1 (en) 1990-01-03
FI840603A0 (fi) 1984-02-15
DE3480925D1 (de) 1990-02-08
ES8603878A1 (es) 1986-01-16
SU1349700A3 (ru) 1987-10-30
NO840551L (no) 1984-08-17
PT78106B (en) 1986-06-02
NO164476C (no) 1990-10-10
ES544203A0 (es) 1986-01-16
AU572118B2 (en) 1988-05-05
KR840007727A (ko) 1984-12-10
PL143010B1 (en) 1987-12-31
GR79543B (es) 1984-10-30
PT78106A (en) 1984-03-01
AU2460584A (en) 1984-08-23
HU189886B (en) 1986-08-28
PL253010A1 (en) 1985-09-10
EP0116948A3 (en) 1984-12-19
NO164476B (no) 1990-07-02
US4490371A (en) 1984-12-25
ES544202A0 (es) 1986-01-16
ES8604226A1 (es) 1986-02-01
IL70964A (en) 1987-08-31
JPS59155383A (ja) 1984-09-04
ATE49210T1 (de) 1990-01-15
PL142960B1 (en) 1987-12-31
PL253009A1 (en) 1985-09-10
ES529749A0 (es) 1986-02-01
CA1253862A (en) 1989-05-09
FI840603A7 (fi) 1984-08-17
IL70964A0 (en) 1984-05-31
NZ207156A (en) 1987-07-31
PL142959B1 (en) 1987-12-31
FI78097C (fi) 1989-06-12
DK70784A (da) 1984-08-17
PL246224A1 (en) 1985-08-27
ZA841122B (en) 1985-09-25
EP0116948A2 (en) 1984-08-29
DK70784D0 (da) 1984-02-15
FI78097B (fi) 1989-02-28

Similar Documents

Publication Publication Date Title
ES8603879A1 (es) Procedimiento para preparar (2-oxo-1,2,3,5-tetrahidroimidazo(2,1-b) quinazolinil) oxialquilamidas
ES8206491A1 (es) Un procedimiento para la preparacion de derivados de 2,4-diaminoquinazolina.
ES8303382A1 (es) Un procedimiento para la preparacion de derivados del 1,2,5-tiadiazol.
ES8404346A1 (es) Un procedimiento para la preparacion de diarilpirazinas o triazinas.
ES8800664A1 (es) Procedimiento para preparar nuevos compuestos sulfonilaminoetilicos
ES8704949A1 (es) Procedimiento para preparar nuevas amidas de acidos tieno-triazolo-1,4-diazepino-2-carboxilicos
ES8106139A1 (es) Procedimiento de preparar compuestos amidicos
ES8306110A1 (es) "procedimiento para la preparacion de derivados de urea".
ES8703410A1 (es) Procedimiento para preparar guanidinas anti-inflamatorias
ES8401025A1 (es) Procedimiento para la obtencion de acidos 1-carboxi-(azaalcanoil o azaaralcanoil)-indolin-2-carboxilicos.
ES8301978A1 (es) Un procedimiento para la preparacion de 2-guanidino-4-heteroaril-tiazoles.
ES8704965A1 (es) Un procedimiento para la preparacion de un antibiotico de macrolida
ES8301966A1 (es) Procedimiento para preparar derivados de pirimidona
ES8703437A1 (es) Procedimiento para la preparacion de 4h-3,1-benzoxazin-4-- onas y compuestos relacionados
ES8403453A1 (es) Un procedimiento para preparar amidas del acido 1-metil-5-p-toluoilpirrol-2-acetico.
ES8404671A1 (es) Un procedimiento para la preparacion de derivados del acido fenoxialquilcarboxilico.
ES8307824A1 (es) Un procedimiento para preparar nuevos compuestos de cefem.
ES8506707A1 (es) Un derivado de acido tiazolilacetico
ES8301883A1 (es) Procedimiento para la preparacion de derivados de ciclohexe-no
ES8704503A1 (es) Procedimiento para preparar sales de ciclimonio
ES8705224A1 (es) Procedimiento para la obtencion de imidazoles sustituidos
ES8606348A1 (es) Un metodo para preparar un derivado de 9-bencilpurina
ES8406424A1 (es) Procedimiento para preparar derivados de guanidina.
ES8604165A1 (es) Procedimiento para preparar nuevos bencimidazoles
ES8702390A1 (es) Un procedimiento para la preparacion de nuevos derivados de 1,5-benzotiazepina